New asthma drug shows promise in small trial
NCT ID NCT05280418
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested tezepelumab, a monoclonal antibody, in 27 adults with uncontrolled moderate-to-severe asthma. The goal was to see if it improves lung function and reduces airway inflammation and blockages. Participants received either tezepelumab or a placebo, and researchers used advanced imaging to measure changes over 16 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tezepelumab (a monoclonal antibody)
What this could lead to
If successful, this could lead to a new treatment option that improves lung function and reduces airway blockages in people with uncontrolled asthma.
What could go wrong
This is a small, early-stage study with only 27 participants, so results may not apply to everyone. The drug may not show significant benefits over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Firestone Institute for Respiratory Health
Hamilton, Ontario, L8N 4A6, Canada